<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Doherty, Michael</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">New Therapies for Gout</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">32-33</style></pages><abstract><style  face="normal" font="default" size="100%">A key objective of long-term management of gout is “cure.” This can be achieved by patient education, modification of the patient's risk factors (diet, obesity, hypertension, lipid levels), and by maintaining tissue urate levels below the saturation point for crystal formation (serum uric acid &lt;360 ümol/l or 6 mg/dl) [Zhang W et al. Ann Rheum Dis 2006].</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">7</style></volume></record></records></xml>